- Stocks
- Pharma & Healthcare
- Earkart
Earkart share price
NSE: EARKARTPharma & HealthcareMedical Devices
Earkart at a glance
With a market capitalisation of ₹182 Cr, it ranks 2332nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Devices.
Its return on equity was 34.6% in FY25. Promoters held 57.34% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹182 CrRank 2332 on NSE
- Price to book
- 0×FY25
- ROE
- 34.6%FY25
- ROCE
- 46.9%FY25
- Debt to equity
- 0.25FY25
- Net profit margin
- 16.0%FY25
- Book value / share
- ₹19.08FY25
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Earkart financials
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | ₹6 Cr | ₹29 Cr | ₹32 Cr | ₹43 Cr |
| Operating profit | ₹0 Cr | ₹1 Cr | ₹3 Cr | ₹9 Cr |
| Net profit | ₹0 Cr | ₹1 Cr | ₹3 Cr | ₹7 Cr |
| EPS (₹) | ₹20.00 | ₹0.87 | ₹2.03 | ₹6.59 |
| Cash from operations | ₹0 Cr | −₹0 Cr | −₹1 Cr | ₹1 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹5 Cr | ₹7 Cr | ₹13 Cr | ₹20 Cr |
Earkart shareholding pattern
| Holder | 2 Oct 2025 | 31 Mar 2026 |
|---|---|---|
| Promoters | 57.34% | 57.34% |
| Domestic institutions | 12.61% | 21.95% |
| Non-institutions | 24.90% | 20.71% |
Earkart vs peers
The listed Pharma & Healthcare companies nearest to Earkart by market capitalisation.
Ask anything about Earkart
Pivot answers on the live chart with evidence you can check, and tests strategies against EARKART's own history. Try: “Why has EARKART moved over the last three months?” · “Backtest a 50-day moving-average crossover on EARKART over five years” · “Compare EARKART with AASHKA on margins and valuation”
Frequently asked questions about Earkart
What is the market cap of Earkart?
Earkart's market capitalisation is ₹182 Cr (₹182 Cr) at the 19 Oct 2026 close, ranking 2332nd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Earkart?
Return on equity was 34.6% in FY25 and return on capital employed was 46.9% in FY25 (standalone figures).
Is Earkart a debt-free company?
No. Earkart's debt-to-equity ratio was 0.25 in FY25, with total debt of ₹0 Cr.
What is the shareholding pattern of Earkart?
As of 31 Mar 2026: promoters 57.34%, domestic institutions 21.95%, non-institutions 20.71%.
Who are Earkart's competitors?
The listed Pharma & Healthcare companies closest to Earkart by market cap are Aashka Hospital, OXYGENTA PHARMA, Accretion Nutra, Novelix Pharma, Medico Remedies and Take Solutions.
Is Earkart a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Earkart's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on EARKART against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with E · all NSE stocks · this page as text